Aristotle Capital Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
Other funds holding EW
Aristotle Capital Management's EW Position: Q3 2026 in Review
Aristotle Capital Management reduced its Edwards Lifesciences (EW) stake by 6.3% in Q3 2026, selling an estimated $48.7M and leaving 8,117,608 shares worth $701M. The position accounts for 1.6% of the portfolio, ranked #27.
Aristotle Capital Management first reported a position in EW in Q2 2026 and has held it in 2 quarters since. The position peaked at $784M in Q2 2026. 1,344 funds tracked by Wall St. Rank hold EW as of Q3 2026.
- Aristotle Capital Management held 8,117,608 shares of Edwards Lifesciences worth $701M as of Q3 2026.
- Aristotle Capital Management sold 548,104 Edwards Lifesciences shares in Q3 2026, an estimated $48.7M.
- Edwards Lifesciences made up 1.6% of Aristotle Capital Management's portfolio in Q3 2026, its #27 holding.
- Aristotle Capital Management first reported a position in Edwards Lifesciences in Q2 2026 and has held it in 2 quarters since.
- Aristotle Capital Management's Edwards Lifesciences position peaked at $784M in Q2 2026.
- 1,344 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.
Based on Aristotle Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.